Lauren P Lashua1, Jeffrey A Melvin1, Berthony Deslouches2, Joseph M Pilewski3, Ronald C Montelaro2, Jennifer M Bomberger4. 1. Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA. 2. Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA. 3. Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA jbomb@pitt.edu.
Abstract
OBJECTIVES: Chronic infections with the opportunistic pathogen Pseudomonas aeruginosa are responsible for the majority of the morbidity and mortality in patients with cystic fibrosis (CF). While P. aeruginosa infections may initially be treated successfully with standard antibiotics, chronic infections typically arise as bacteria transition to a biofilm mode of growth and acquire remarkable antimicrobial resistance. To address the critical need for novel antimicrobial therapeutics that can effectively suppress chronic bacterial infections in challenging physiological environments, such as the CF lung, we have rationally designed a de novo engineered cationic antimicrobial peptide, the 24-residue WLBU2, with broad-spectrum antibacterial activity for pan-drug-resistant P. aeruginosa in liquid culture. In the current study, we tested the hypothesis that WLBU2 also prevents P. aeruginosa biofilm growth. METHODS: Using abiotic and biotic biofilm assays, co-culturing P. aeruginosa with polarized human airway epithelial cells, we examined the ability of WLBU2 to prevent biofilm biogenesis alone and in combination with currently used antibiotics. RESULTS: We observed a dose-dependent reduction in biofilm growth on an abiotic surface and in association with CF airway epithelial cells. WLBU2 prevented P. aeruginosa biofilm formation when co-cultured with mucus-producing primary human CF airway epithelial cells and using CF clinical isolates of P. aeruginosa, even at low pH and high salt conditions that mimic the CF airway. When used in combination, WLBU2 significantly increases killing by the commonly used antibiotics tobramycin, ciprofloxacin, ceftazidime and meropenem. CONCLUSIONS: While other studies have demonstrated the ability of natural and synthetic antimicrobial peptides to prevent abiotic bacterial biofilm formation, the current studies for the first time demonstrate the effective peptide treatment of a biotic bacterial biofilm in a setting similar to the CF airway, and without negative effects on human airway epithelial cells, thus highlighting the unique potential of this engineered cationic antimicrobial peptide for treatment of human respiratory infections.
OBJECTIVES:Chronic infections with the opportunistic pathogen Pseudomonas aeruginosa are responsible for the majority of the morbidity and mortality in patients with cystic fibrosis (CF). While P. aeruginosa infections may initially be treated successfully with standard antibiotics, chronic infections typically arise as bacteria transition to a biofilm mode of growth and acquire remarkable antimicrobial resistance. To address the critical need for novel antimicrobial therapeutics that can effectively suppress chronic bacterial infections in challenging physiological environments, such as the CF lung, we have rationally designed a de novo engineered cationic antimicrobial peptide, the 24-residue WLBU2, with broad-spectrum antibacterial activity for pan-drug-resistant P. aeruginosa in liquid culture. In the current study, we tested the hypothesis that WLBU2 also prevents P. aeruginosa biofilm growth. METHODS: Using abiotic and biotic biofilm assays, co-culturing P. aeruginosa with polarized human airway epithelial cells, we examined the ability of WLBU2 to prevent biofilm biogenesis alone and in combination with currently used antibiotics. RESULTS: We observed a dose-dependent reduction in biofilm growth on an abiotic surface and in association with CF airway epithelial cells. WLBU2 prevented P. aeruginosa biofilm formation when co-cultured with mucus-producing primary human CF airway epithelial cells and using CF clinical isolates of P. aeruginosa, even at low pH and high salt conditions that mimic the CF airway. When used in combination, WLBU2 significantly increases killing by the commonly used antibiotics tobramycin, ciprofloxacin, ceftazidime and meropenem. CONCLUSIONS: While other studies have demonstrated the ability of natural and synthetic antimicrobial peptides to prevent abiotic bacterial biofilm formation, the current studies for the first time demonstrate the effective peptide treatment of a biotic bacterial biofilm in a setting similar to the CF airway, and without negative effects on human airway epithelial cells, thus highlighting the unique potential of this engineered cationic antimicrobial peptide for treatment of humanrespiratory infections.
Authors: Eric E Smith; Danielle G Buckley; Zaining Wu; Channakhone Saenphimmachak; Lucas R Hoffman; David A D'Argenio; Samuel I Miller; Bonnie W Ramsey; David P Speert; Samuel M Moskowitz; Jane L Burns; Rajinder Kaul; Maynard V Olson Journal: Proc Natl Acad Sci U S A Date: 2006-05-10 Impact factor: 11.205
Authors: Berthony Deslouches; Kazi Islam; Jodi K Craigo; Shruti M Paranjape; Ronald C Montelaro; Timothy A Mietzner Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: Berthony Deslouches; Jonathan D Steckbeck; Jodi K Craigo; Yohei Doi; Timothy A Mietzner; Ronald C Montelaro Journal: Antimicrob Agents Chemother Date: 2013-03-18 Impact factor: 5.191
Authors: Alejandro A Pezzulo; Xiao Xiao Tang; Mark J Hoegger; Mahmoud H Abou Alaiwa; Shyam Ramachandran; Thomas O Moninger; Phillip H Karp; Christine L Wohlford-Lenane; Henk P Haagsman; Martin van Eijk; Botond Bánfi; Alexander R Horswill; David A Stoltz; Paul B McCray; Michael J Welsh; Joseph Zabner Journal: Nature Date: 2012-07-04 Impact factor: 49.962
Authors: Frank Heinrich; Aria Salyapongse; Akari Kumagai; Fernando G Dupuy; Karpur Shukla; Anja Penk; Daniel Huster; Robert K Ernst; Anna Pavlova; James C Gumbart; Berthony Deslouches; Y Peter Di; Stephanie Tristram-Nagle Journal: Chemistry Date: 2020-04-28 Impact factor: 5.236